Logiscreen

Aytu BioPharma Inc

$2.25
Market Cap 24.15M
ROE -148.9%
Gross Margin 61.2%
Debt/Equity 0.6
Current Ratio 1.1
Revenue QoQ -32.7%
EPS QoQ -1.8%
F-Score 2

About

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT ® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT ® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal ® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor ® and Tri-Vi-Flor ®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-0.67
vs median 33.61
P/B
0.65
vs median 2.16
ROE
-1.49
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics